Yves Fradet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Yves Fradet has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
Alain Bergeron
Université Laval, Quebec City, QC, Canada
9 shared publications- Louis Lacombe
Research Centre of CHU de Québec-Université Laval, Québec City, Québec, Canada
6 shared publications - Bernard Têtu
Department of Pathology and Research Center, CHUQ, L'Hôtel-Dieu de Québec, Quebec, QC, Canada
5 shared publications Hélène LaRue
Centre de Recherche en Cancérologie de l'Université Laval, CHU de Québec-L'Hôtel-Dieu de Québec, 10 McMahon, Québec, QC G1R 3S1, Canada
5 shared publicationsLouis Lacombe
Centre de recherche en cancérologie de l'Université Laval, L'Hôtel-Dieu de Québec, Centre hospitalier universitaire de Québec, Québec, Canada
5 shared publications- Wassim Kassouf
Department of Surgery, McGill University, Montreal, Quebec, Canada
5 shared publications
Latest Publications
- 30 October 2017
- Published by Taylor & Francis in Nutrition and Cancer
- Vol. 69 (8) , 1196-1204
Prospective Evaluation of Nutritional Factors to Predict the Risk of Complications for Patients Undergoing Radical Cystectomy: A Cohort Study
The objective of this study was to identify nutritional preoperative factors associated with complications after radical cystectomy (RC). We prospectively evaluated the Mini-Nutritional Assessment Score, body mass index (BMI), appetite, stool frequency, hydration, food intake, weight loss, albuminemia, and prealbuminemia of 144 patients who underwent RC between January 2011 and April 2014. Postoperative complications were defined as any adverse event reported in the patient's file up to 90 days after surgery. Each complication was classified according to the Clavien–Dindo and Memorial Sloan–Kettering Cancer Center systems. The adjusted relative risk (RR) computed through a Poisson regression model was used to identify nutritional risk factors associated with post-RC complications. A high BMI >27 kg/m2 was associated with higher risk of low-grade complications (RR:1.47 [95% CI,1.09–2.00]) at 7 days and a four-fold increased risk of cardiac complications at 7 and 90 days (RR:3.77 [1.15–12.32] and RR:3.28 [1.35–7.98]). Decreased appetite was associated with low-grade (RR:1.43 [1.03–1.99] complications within 90 days. Preoperative weight loss >3 kg was associated with high-grade (RR:2.49 [1.23–5.05]) and wound (RR:2.51 [1.23–5.10]) complications within 90 days. This study showed that preoperative nutritional status of patients may predict the occurrence of complications up to 90 days post-RC. Development of preoperative nutritional interventions may reduce the deleterious impact of RC on patients' health.
- 30 October 2017
- Published by Taylor & Francis in Nutrition and Cancer
- Vol. 69 (8) , 1196-1204
Prospective Evaluation of Nutritional Factors to Predict the Risk of Complications for Patients Undergoing Radical Cystectomy: A Cohort Study
The objective of this study was to identify nutritional preoperative factors associated with complications after radical cystectomy (RC). We prospectively evaluated the Mini-Nutritional Assessment Score, body mass index (BMI), appetite, stool frequency, hydration, food intake, weight loss, albuminemia, and prealbuminemia of 144 patients who underwent RC between January 2011 and April 2014. Postoperative complications were defined as any adverse event reported in the patient's file up to 90 days after surgery. Each complication was classified according to the Clavien–Dindo and Memorial Sloan–Kettering Cancer Center systems. The adjusted relative risk (RR) computed through a Poisson regression model was used to identify nutritional risk factors associated with post-RC complications. A high BMI >27 kg/m2 was associated with higher risk of low-grade complications (RR:1.47 [95% CI,1.09–2.00]) at 7 days and a four-fold increased risk of cardiac complications at 7 and 90 days (RR:3.77 [1.15–12.32] and RR:3.28 [1.35–7.98]). Decreased appetite was associated with low-grade (RR:1.43 [1.03–1.99] complications within 90 days. Preoperative weight loss >3 kg was associated with high-grade (RR:2.49 [1.23–5.05]) and wound (RR:2.51 [1.23–5.10]) complications within 90 days. This study showed that preoperative nutritional status of patients may predict the occurrence of complications up to 90 days post-RC. Development of preoperative nutritional interventions may reduce the deleterious impact of RC on patients' health.
- 10 January 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (2_suppl) , 96
Copy number alterations of DNA mismatch repair (MMR) genes as novel prognostic markers in localised prostate cancer (CaP).
96 Background: To investigate the prognostic significance of CNA of genes involved in the MMR pathway in localised CaP. Methods: We studied CNA of genes involved in MMR, namely MSH2, MSH3, MSH6, MLH1, PMS2, in 284 patients with intermediate-risk CaP (Toronto cohort), and compared our findings against three public databases (MSKCC and Cambridge cohorts) that included 375 low- to high-risk CaP. The Toronto cohort comprised of 143 and 141 individuals who underwent image-guided radiotherapy (IGRT) and radical prostatectomy (RadP), respectively, while all patients from the public databases underwent RadP. Information on genome-wide copy number alterations (Toronto) was obtained using Affymetrix Oncoscan array. Biochemical relapse-free survival (bRFS) was assessed for clinical outcome. Results: CNA of MSH2, MSH3, MSH6, MLH1, PMS2 were observed in 3.9% (n = 11), 7.7% (n = 22), 3.9% (n = 11), 4.6% (n = 13) and 13.0% (n = 37) of the Toronto cohort, respectively. Distinct patterns of allelic gain and loss were observed for the gene set; gains only for MLH1 and PMS2, and losses only, in all but 1 case, for MSH2, MSH3 and MSH6. In the Toronto cohort, allelic losses of MSH2, MSH3 and MSH6 were determined to be prognostic for poorer bRFS in IGRT patients (HR 2.04, 95% CI 1.01, 4.12, p = 0.048), but not for patients who underwent RadP (HR 1.08, 95% CI 0.49, 2.39, p = 0.84); while gains in MLH1 and PMS2 were not prognostic in either IGRT or RadP patients. A pooled analysis of these genes for all RadP patients from the Toronto and public databases (n = 516) did however indicate that allelic losses of MSH2, MSH3 and MSH6 were significant predictors of poorer bRFS (HR 2.48, 95% CI 1.64-3.77, p < 0.001), but not MLH1 and PMS2 gains. On multi-variable modelling that includes percent genome aberration and pre-treatment PSA levels, allelic losses of MSH2, MSH3 and MSH6remained significant predictors of bRFS for the pooled RadP cohort (HR 1.96, 95% CI 1.27, 3.01, Wald's p < 0.001), but not for IGRT patients (HR 1.50, 95% CI 0.72, 3.12, p = 0.28). Conclusions: We identified a distinct pattern of copy number loss of MSH2, MSH3 and MSH6 genes in localised CaP that appears to be a novel biomarker of failure to definitive treatment.
- 10 January 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (2_suppl) , 96
Copy number alterations of DNA mismatch repair (MMR) genes as novel prognostic markers in localised prostate cancer (CaP).
96 Background: To investigate the prognostic significance of CNA of genes involved in the MMR pathway in localised CaP. Methods: We studied CNA of genes involved in MMR, namely MSH2, MSH3, MSH6, MLH1, PMS2, in 284 patients with intermediate-risk CaP (Toronto cohort), and compared our findings against three public databases (MSKCC and Cambridge cohorts) that included 375 low- to high-risk CaP. The Toronto cohort comprised of 143 and 141 individuals who underwent image-guided radiotherapy (IGRT) and radical prostatectomy (RadP), respectively, while all patients from the public databases underwent RadP. Information on genome-wide copy number alterations (Toronto) was obtained using Affymetrix Oncoscan array. Biochemical relapse-free survival (bRFS) was assessed for clinical outcome. Results: CNA of MSH2, MSH3, MSH6, MLH1, PMS2 were observed in 3.9% (n = 11), 7.7% (n = 22), 3.9% (n = 11), 4.6% (n = 13) and 13.0% (n = 37) of the Toronto cohort, respectively. Distinct patterns of allelic gain and loss were observed for the gene set; gains only for MLH1 and PMS2, and losses only, in all but 1 case, for MSH2, MSH3 and MSH6. In the Toronto cohort, allelic losses of MSH2, MSH3 and MSH6 were determined to be prognostic for poorer bRFS in IGRT patients (HR 2.04, 95% CI 1.01, 4.12, p = 0.048), but not for patients who underwent RadP (HR 1.08, 95% CI 0.49, 2.39, p = 0.84); while gains in MLH1 and PMS2 were not prognostic in either IGRT or RadP patients. A pooled analysis of these genes for all RadP patients from the Toronto and public databases (n = 516) did however indicate that allelic losses of MSH2, MSH3 and MSH6 were significant predictors of poorer bRFS (HR 2.48, 95% CI 1.64-3.77, p < 0.001), but not MLH1 and PMS2 gains. On multi-variable modelling that includes percent genome aberration and pre-treatment PSA levels, allelic losses of MSH2, MSH3 and MSH6remained significant predictors of bRFS for the pooled RadP cohort (HR 1.96, 95% CI 1.27, 3.01, Wald's p < 0.001), but not for IGRT patients (HR 1.50, 95% CI 0.72, 3.12, p = 0.28). Conclusions: We identified a distinct pattern of copy number loss of MSH2, MSH3 and MSH6 genes in localised CaP that appears to be a novel biomarker of failure to definitive treatment.
- 10 January 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (2_suppl) , 49
Prognostic value of copy-number alterations of the Cohesin complex in intermediate-risk prostate cancer recurrence.
49 Background: The Cohesin complex plays a critical role in mitotic progression and post-replicative DNA damage repair. It serves to bring together sister chromatids both in metaphase and in homologous recombination repair following ionizing radiation. The complex has also been shown to be phosphorylated in the ATM/BRCA1 pathway. The expression of various proteins in the complex are dysregulated in many cancers: breast, prostate, etc. Interestingly, in breast cancer cell lines, Cohesin is required for MYC activation in response to estrogen. Our study sought to correlate copy number alterations in this pivotal complex with biochemical relapse in prostate cancer patients. Methods: Our cohort consists of 284 patients with D’ Amico-classified intermediate-risk prostate cancer, treated with image-guided radiotherapy (IGRT, N = 143) or radical prostatectomy (RadP, N = 141). Pre-treatment biopsies and prostatectomy samples were analyzed using the Affymetrix Oncoscan array. The Phoenix and AUA criteria was used to define biochemical relapse for RadP and IGRT patients respectively. Results: Copy number alterations of RAD21, SMC1B, and STAG1 were observed in 18% (n = 52), 6.3% (n = 18), and 12% (n = 35) of the cohort respectively. They were predominantly losses in SMC1B, but gains in RAD21 and STAG1. All three genes in the Cohesin complex were associated with increased risk of biochemical relapse: RAD21 on chromosome 8 (HR = 1.93, 95% CI 1.23, 3.02, Wald’s p = 0.004), SMC1B on chromosome 22 (HR = 3.37, 95% CI 1.91, 5.94, Wald’s p < 10-4), and STAG1 on chromosome 3 (HR = 1.74, 95% CI 1.04, 2.89, Wald’s p < 0.05). However, when controlled for percent genome alteration and pre-treatment serum PSA levels, only copy number loss of SMC1B was a significant predictor of biochemical relapse (HR = 2.95, 95% CI 1.62, 5.38, Wald’s p < 10-3). Conclusions: We identified a novel association of copy-number alterations in members of the Cohesin complex with biochemical recurrence following radical prostatectomy or image-guided radiotherapy. This points to the central role of Cohesin in cell-cycle and DNA damage pathways promoting prostate cancer progression.
- 10 January 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (2_suppl) , 49
Prognostic value of copy-number alterations of the Cohesin complex in intermediate-risk prostate cancer recurrence.
49 Background: The Cohesin complex plays a critical role in mitotic progression and post-replicative DNA damage repair. It serves to bring together sister chromatids both in metaphase and in homologous recombination repair following ionizing radiation. The complex has also been shown to be phosphorylated in the ATM/BRCA1 pathway. The expression of various proteins in the complex are dysregulated in many cancers: breast, prostate, etc. Interestingly, in breast cancer cell lines, Cohesin is required for MYC activation in response to estrogen. Our study sought to correlate copy number alterations in this pivotal complex with biochemical relapse in prostate cancer patients. Methods: Our cohort consists of 284 patients with D’ Amico-classified intermediate-risk prostate cancer, treated with image-guided radiotherapy (IGRT, N = 143) or radical prostatectomy (RadP, N = 141). Pre-treatment biopsies and prostatectomy samples were analyzed using the Affymetrix Oncoscan array. The Phoenix and AUA criteria was used to define biochemical relapse for RadP and IGRT patients respectively. Results: Copy number alterations of RAD21, SMC1B, and STAG1 were observed in 18% (n = 52), 6.3% (n = 18), and 12% (n = 35) of the cohort respectively. They were predominantly losses in SMC1B, but gains in RAD21 and STAG1. All three genes in the Cohesin complex were associated with increased risk of biochemical relapse: RAD21 on chromosome 8 (HR = 1.93, 95% CI 1.23, 3.02, Wald’s p = 0.004), SMC1B on chromosome 22 (HR = 3.37, 95% CI 1.91, 5.94, Wald’s p < 10-4), and STAG1 on chromosome 3 (HR = 1.74, 95% CI 1.04, 2.89, Wald’s p < 0.05). However, when controlled for percent genome alteration and pre-treatment serum PSA levels, only copy number loss of SMC1B was a significant predictor of biochemical relapse (HR = 2.95, 95% CI 1.62, 5.38, Wald’s p < 10-3). Conclusions: We identified a novel association of copy-number alterations in members of the Cohesin complex with biochemical recurrence following radical prostatectomy or image-guided radiotherapy. This points to the central role of Cohesin in cell-cycle and DNA damage pathways promoting prostate cancer progression.
- 10 January 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (2_suppl) , 117
Copy number alterations of P53, RB1, and MDM2 as prognostic markers in intermediate-risk prostate cancer.
117 Background: We interrogated copy number alternations (CNA) of p53, Rb1 and MDM2 as prognostic determinants of biochemical failure in localized intermediate-risk prostate cancer. Methods: Using Affymetrix Oncoscan array technology, we characterized copy number alterations (CNA) for 284 D’Amico-classified intermediate-risk prostate cancers. Of the 284 patients, 143 underwent image-guided radiotherapy (IGRT), while 141 underwent radical prostatectomy (RadP). Biochemical-relapse free survival (bRFS) was assessed as a clinical end-point, with biochemical failure defined using the Phoenix and AUA criteria for IGRT and RadP patients, respectively. Results: We observed allelic losses ofp53 and Rb1 in 23.9% (n = 68) and 31.0% (n = 88) and allelic gains of MDM2 in 3.17% (n = 9) in our cohort, respectively. 7.7% (n = 22), 1.1% (n = 3) and 0.4% (n = 1) of all cases exhibited concurrent losses of p53 and Rb1, p53 loss and MDM2 gain, and concurrent p53/Rb1 loss and MDM2 gain, respectively. Patients with allelic losses of p53, Rb1 and allelic gain of MDM2 loci exhibited increased percent genome aberration (PGA) (Mean 9.2 vs. 6.1 p < 0.001; 10.1 vs. 5.4 p < 0.001; 18.1 vs. 6.5 p < 0.001 respectively). Rb1 loss and MDM2 gain were not significant predictors of bRFS, independent of treatment modality. Allelic loss of p53 was predictive of poor bRFS in the RadP cohort (HR = 1.86, 95% CI 1.10-3.16, p = 0.022), but not for IGRT patients (HR = 1.16, 95% CI 0.63-2.12, p = 0.629). Additionally, patients in the RadP cohort with concurrent losses of p53 and Rb1 also had a higher likelihood of poorer bRFS (HR = 2.32, 95% CI 1.1-4.93, p = 0.029). On multivariate analysis, incorporating PGA and pre-treatment PSA, concurrent p53/Rb1 losses, but not single p53 loss, was prognostic for bRFS in patients who underwent RadP (p53/Rb1 losses, HR = 2.16, 95% CI 1.0-4.65, Wald's p = 0.05; p53loss, HR = 1.62, 95% CI 0.94-2.79, Wald's p = 0.08). Conclusions: In a cohort of men with intermediate-risk prostate cancers, we identified an unfavourable subgroup of patients harbouring concurrent copy number losses of p53 and Rb1 that was associated with an adverse prognosis of biochemical failure following radical prostatectomy.
- 10 January 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (2_suppl) , 117
Copy number alterations of P53, RB1, and MDM2 as prognostic markers in intermediate-risk prostate cancer.
117 Background: We interrogated copy number alternations (CNA) of p53, Rb1 and MDM2 as prognostic determinants of biochemical failure in localized intermediate-risk prostate cancer. Methods: Using Affymetrix Oncoscan array technology, we characterized copy number alterations (CNA) for 284 D’Amico-classified intermediate-risk prostate cancers. Of the 284 patients, 143 underwent image-guided radiotherapy (IGRT), while 141 underwent radical prostatectomy (RadP). Biochemical-relapse free survival (bRFS) was assessed as a clinical end-point, with biochemical failure defined using the Phoenix and AUA criteria for IGRT and RadP patients, respectively. Results: We observed allelic losses ofp53 and Rb1 in 23.9% (n = 68) and 31.0% (n = 88) and allelic gains of MDM2 in 3.17% (n = 9) in our cohort, respectively. 7.7% (n = 22), 1.1% (n = 3) and 0.4% (n = 1) of all cases exhibited concurrent losses of p53 and Rb1, p53 loss and MDM2 gain, and concurrent p53/Rb1 loss and MDM2 gain, respectively. Patients with allelic losses of p53, Rb1 and allelic gain of MDM2 loci exhibited increased percent genome aberration (PGA) (Mean 9.2 vs. 6.1 p < 0.001; 10.1 vs. 5.4 p < 0.001; 18.1 vs. 6.5 p < 0.001 respectively). Rb1 loss and MDM2 gain were not significant predictors of bRFS, independent of treatment modality. Allelic loss of p53 was predictive of poor bRFS in the RadP cohort (HR = 1.86, 95% CI 1.10-3.16, p = 0.022), but not for IGRT patients (HR = 1.16, 95% CI 0.63-2.12, p = 0.629). Additionally, patients in the RadP cohort with concurrent losses of p53 and Rb1 also had a higher likelihood of poorer bRFS (HR = 2.32, 95% CI 1.1-4.93, p = 0.029). On multivariate analysis, incorporating PGA and pre-treatment PSA, concurrent p53/Rb1 losses, but not single p53 loss, was prognostic for bRFS in patients who underwent RadP (p53/Rb1 losses, HR = 2.16, 95% CI 1.0-4.65, Wald's p = 0.05; p53loss, HR = 1.62, 95% CI 0.94-2.79, Wald's p = 0.08). Conclusions: In a cohort of men with intermediate-risk prostate cancers, we identified an unfavourable subgroup of patients harbouring concurrent copy number losses of p53 and Rb1 that was associated with an adverse prognosis of biochemical failure following radical prostatectomy.
- 27 August 2013
- Published by Springer Nature in Nature Reviews Urology
- Vol. 10 (9) , 537-545
Toll-like receptors in urothelial cells—targets for cancer immunotherapy
In this Review, LaRue et al. focus on the expression and role of toll-like receptors (TLRs) in normal and tumour urothelial cells and the potential use of TLR agonists for bladder cancer treatment. Toll-like receptors (TLRs) have an important role in the activation of both innate and adaptive immunity in response to pathogens and danger signals. These receptors are expressed in immune cells and in some epithelia. They are expressed in the epithelium of the urinary bladder, where they actively participate in the fight against infection by uropathogens. TLR expression is decreased (although still evident) in bladder tumours, especially in non-muscle-invasive tumours. Intravesical immunotherapy with BCG to prevent recurrence of these tumours has been shown to involve the participation of three different TLRs (TLR2, TLR4, and TLR9). However, alternative therapies are needed as BCG fails in some patients and can sometimes cause severe adverse effects that are difficult to tolerate. In recent years, TLR2, TLR4, TLR7, and TLR9 agonists have been tested in vitro and in vivo for their ability to activate an antitumour immune response against bladder cancer. Promising results from these studies have led to the testing of TLR7 and TLR9 agonists in clinical trials.
- 27 August 2013
- Published by Springer Nature in Nature Reviews Urology
- Vol. 10 (9) , 537-545
Toll-like receptors in urothelial cells—targets for cancer immunotherapy
In this Review, LaRue et al. focus on the expression and role of toll-like receptors (TLRs) in normal and tumour urothelial cells and the potential use of TLR agonists for bladder cancer treatment. Toll-like receptors (TLRs) have an important role in the activation of both innate and adaptive immunity in response to pathogens and danger signals. These receptors are expressed in immune cells and in some epithelia. They are expressed in the epithelium of the urinary bladder, where they actively participate in the fight against infection by uropathogens. TLR expression is decreased (although still evident) in bladder tumours, especially in non-muscle-invasive tumours. Intravesical immunotherapy with BCG to prevent recurrence of these tumours has been shown to involve the participation of three different TLRs (TLR2, TLR4, and TLR9). However, alternative therapies are needed as BCG fails in some patients and can sometimes cause severe adverse effects that are difficult to tolerate. In recent years, TLR2, TLR4, TLR7, and TLR9 agonists have been tested in vitro and in vivo for their ability to activate an antitumour immune response against bladder cancer. Promising results from these studies have led to the testing of TLR7 and TLR9 agonists in clinical trials.
- 1 May 2013
- Published by Canadian Urological Association Journal in Canadian Urological Association Journal
- Vol. 3 (3-S2) , 102-S108
The burden of prostate cancer in Canada
The clinical and economic burden of prostate cancer in Canada is substantial,and is rising. Studies indicate that 1 in 7 men will develop prostate cancer duringtheir lifetime, and another 1 in 27 will die because of it. It is estimated that4300 Canadian men will die of prostate cancer in 2008. Age, family history, raceand diet are all risks associated with the development of prostate cancer. A diagnosisof cancer carries a significant burden and like other cancers is a cause ofsignificant anxiety and depression. Uncertainty regarding the value of screeningfor prostate cancer has been, and continues to be, a challenge for primarycare physicians and urologists.
- 1 May 2013
- Published by Canadian Urological Association Journal in Canadian Urological Association Journal
- Vol. 3 (3-S2) , 102-S108
The burden of prostate cancer in Canada
The clinical and economic burden of prostate cancer in Canada is substantial,and is rising. Studies indicate that 1 in 7 men will develop prostate cancer duringtheir lifetime, and another 1 in 27 will die because of it. It is estimated that4300 Canadian men will die of prostate cancer in 2008. Age, family history, raceand diet are all risks associated with the development of prostate cancer. A diagnosisof cancer carries a significant burden and like other cancers is a cause ofsignificant anxiety and depression. Uncertainty regarding the value of screeningfor prostate cancer has been, and continues to be, a challenge for primarycare physicians and urologists.
- Open Access
- 1 May 2013
- Published by Canadian Urological Association Journal in Canadian Urological Association Journal
- Vol. 3 (6) , 486-7
Arguments against investing widely in robotic prostatectomy in Canada: a wrong focus on tool box rather than surgical expertise
- 1 May 2013
- Published by Canadian Urological Association Journal in Canadian Urological Association Journal
- Vol. 3 (6) , 486-7
Open AccessArguments against investing widely in robotic prostatectomy in Canada: a wrong focus on tool box rather than surgical expertise
- 2 April 2013
- Published by Canadian Urological Association Journal in Canadian Urological Association Journal
- Vol. 5 (2) , 83
Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience
Background: Radical cystectomy may provide optimal survivaloutcomes in the management of clinical T1 bladder cancer. Wepresent our data from a large, multi-institutional, contemporaryCanadian series of patients who underwent radical cystectomy forclinical T1 bladder cancer in a single-payer health care system.Methods: We collected a pooled database of 2287 patients whounderwent radical cystectomy between 1993 and 2008 in 8 differentcentres across Canada; 306 of these patients had clinical T1bladder cancer. Survival data were analyzed using Kaplan-Meiermethod and Cox regression analysis.Results: The median age of patients was 67 years with a mean follow-up time of 35 months. The 5-year overall, disease-specific anddisease-free survival was 71%, 77% and 59%, respectively. The10-year overall and disease-specific survival were 60% and 67%,respectively. Pathologic stage distribution was p0: 32 (11%), pT1:78 (26%), pT2: 55 (19%), pT3: 60 (20%), pT4: 27 (9%), pTa: 16(5%), pTis: 28 (10%), pN0: 215 (74%) and pN1-3: 78 (26%). Only12% of patients were given adjuvant chemotherapy. On multivariateanalysis, only margin status and pN stage were independentlyassociated with overall, disease-specific and disease-free survival.Interpretation: These results indicate that clinical T1 bladder cancermay be significantly understaged. Identifying factors associatedwith understaged and/or disease destined to progress (despite anyprior intravesical or repeat transurethral therapies prior to radicalcystectomy) will be critical to improve survival outcomes withoutover-treating clinical T1 disease that can be successfully managedwith bladder preservation strategies.Contexte : La cystectomie radicale peut donner des résultats optimauxen lien avec la survie dans la prise en charge d’un cancerde la vessie de stade clinique T1. Nous présentons ici les donnéesprovenant d’une récente étude multicentrique de grande envergureportant sur des patients canadiens ayant subi une cystectomie radicalepour le traitement d’un cancer de la vessie de stade cliniqueT1 dans un système de santé à payeur unique.Méthodologie : Nous avons cumulé les données provenant de2 287 patients ayant subi une cystectomie radicale entre 1993et 2008 dans 8 centres différents au Canada; 306 de ces patientsprésentaient un cancer de la vessie de stade clinique T1. Les donnéesliées à la survie ont été analysées à l’aide de la méthode deKaplan-Meier et du modèle de régression de Cox.Résultats : L’âge médian des patients était de 67 ans, et la duréemoyenne du suivi, de 35 mois. La survie globale, la survie spécifiqueà la maladie et la survie sans maladie après 5 ans étaient de71 %, 77 % et 59%, respectivement. La survie globale et la surviespécifique à la maladie après 10 ans étaient de 60 % et 67 %,respectivement. Les stades pathologiques se répartissaient ainsi :p0 : 32 (11 %), pT1 : 78 (26 %), pT2 : 55 (19 %), pT3 : 60 (20 %),pT4 : 27 (9 %), pTa : 16 (5 %), pTis : 28 (10 %), pN0 : 215 (74 %)et pN1-3 : 78 (26 %). Seulement 12 % des patients ont reçu unechimiothérapie adjuvante. À l’analyse multivariée, seuls le statutdes marges chirurgicales et le stade pN étaient indépendants dela survie globale, la survie spécifique à la maladie et la surviesans maladie.Interprétation : Ces résultats indiquent que le stade d’un cancerde la vessie d’abord classé comme T1 peut avoir été grandementsous-évalué. L’identification des facteurs associés à un cancer dontle stade a été sous-évalué et/ou à une maladie destinée à évoluer(malgré un traitement intravésical antérieur ou des traitementstransurétraux répétés avant la cystectomie radicale) jouera un rôlecrucial dans la hausse des taux de survie sans surtraiter la maladieclinique de stade T1 pouvant être prise en charge de façon efficacepar des stratégies de conservation de la vessie.
- 2 April 2013
- Published by Canadian Urological Association Journal in Canadian Urological Association Journal
- Vol. 5 (2) , 83
Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience
Background: Radical cystectomy may provide optimal survivaloutcomes in the management of clinical T1 bladder cancer. Wepresent our data from a large, multi-institutional, contemporaryCanadian series of patients who underwent radical cystectomy forclinical T1 bladder cancer in a single-payer health care system.Methods: We collected a pooled database of 2287 patients whounderwent radical cystectomy between 1993 and 2008 in 8 differentcentres across Canada; 306 of these patients had clinical T1bladder cancer. Survival data were analyzed using Kaplan-Meiermethod and Cox regression analysis.Results: The median age of patients was 67 years with a mean follow-up time of 35 months. The 5-year overall, disease-specific anddisease-free survival was 71%, 77% and 59%, respectively. The10-year overall and disease-specific survival were 60% and 67%,respectively. Pathologic stage distribution was p0: 32 (11%), pT1:78 (26%), pT2: 55 (19%), pT3: 60 (20%), pT4: 27 (9%), pTa: 16(5%), pTis: 28 (10%), pN0: 215 (74%) and pN1-3: 78 (26%). Only12% of patients were given adjuvant chemotherapy. On multivariateanalysis, only margin status and pN stage were independentlyassociated with overall, disease-specific and disease-free survival.Interpretation: These results indicate that clinical T1 bladder cancermay be significantly understaged. Identifying factors associatedwith understaged and/or disease destined to progress (despite anyprior intravesical or repeat transurethral therapies prior to radicalcystectomy) will be critical to improve survival outcomes withoutover-treating clinical T1 disease that can be successfully managedwith bladder preservation strategies.Contexte : La cystectomie radicale peut donner des résultats optimauxen lien avec la survie dans la prise en charge d’un cancerde la vessie de stade clinique T1. Nous présentons ici les donnéesprovenant d’une récente étude multicentrique de grande envergureportant sur des patients canadiens ayant subi une cystectomie radicalepour le traitement d’un cancer de la vessie de stade cliniqueT1 dans un système de santé à payeur unique.Méthodologie : Nous avons cumulé les données provenant de2 287 patients ayant subi une cystectomie radicale entre 1993et 2008 dans 8 centres différents au Canada; 306 de ces patientsprésentaient un cancer de la vessie de stade clinique T1. Les donnéesliées à la survie ont été analysées à l’aide de la méthode deKaplan-Meier et du modèle de régression de Cox.Résultats : L’âge médian des patients était de 67 ans, et la duréemoyenne du suivi, de 35 mois. La survie globale, la survie spécifiqueà la maladie et la survie sans maladie après 5 ans étaient de71 %, 77 % et 59%, respectivement. La survie globale et la surviespécifique à la maladie après 10 ans étaient de 60 % et 67 %,respectivement. Les stades pathologiques se répartissaient ainsi :p0 : 32 (11 %), pT1 : 78 (26 %), pT2 : 55 (19 %), pT3 : 60 (20 %),pT4 : 27 (9 %), pTa : 16 (5 %), pTis : 28 (10 %), pN0 : 215 (74 %)et pN1-3 : 78 (26 %). Seulement 12 % des patients ont reçu unechimiothérapie adjuvante. À l’analyse multivariée, seuls le statutdes marges chirurgicales et le stade pN étaient indépendants dela survie globale, la survie spécifique à la maladie et la surviesans maladie.Interprétation : Ces résultats indiquent que le stade d’un cancerde la vessie d’abord classé comme T1 peut avoir été grandementsous-évalué. L’identification des facteurs associés à un cancer dontle stade a été sous-évalué et/ou à une maladie destinée à évoluer(malgré un traitement intravésical antérieur ou des traitementstransurétraux répétés avant la cystectomie radicale) jouera un rôlecrucial dans la hausse des taux de survie sans surtraiter la maladieclinique de stade T1 pouvant être prise en charge de façon efficacepar des stratégies de conservation de la vessie.
- 10 December 2012
- Published by Canadian Urological Association Journal in Canadian Urological Association Journal
- Vol. 6 (6) , 455-62
Regional differences in practice patterns and associated outcomes for upper tract urothelial carcinoma in Canada
Introduction: We delineated Canadian regional differences in practice patterns in the management of upper tract urothelial carcinoma (UTUC) after nephroureterectomy and relate these to patient outcomes.Methods: A database was created with 1029 patients undergoing radical nephroureterectomy for UTUC between 1994 and 2009 at 10 Canadian centres. Demographic, clinical and pathological variables were collected from chart review. Practice pattern variables were defined as: open versus laparoscopic nephroureterectomy, management strategy for the distal ureter, performance of lymphadenectomy and administration of chemotherapy and/or radiation therapy. The outcome measures were overall (OS), disease-specific (DSS) and recurrence-free survival (RFS). The centres were divided into three regions (West, Central, East). Cox proportional multivariable linear regression analysis was used to determine the association between regional differences in practice patterns and clinical outcomes.Results: There was a significant difference in practice patterns between regions within Canada for: time from diagnosis to surgery (p = 0.001), type of surgery (open vs. laparoscopic, p < 0.01) and method of management of the distal ureter (p = 0.001). As well, there were significant differences in survival between regions across Canada: 5-year OS (West 70%, Central 81% and East 62%, p < 0.0001) and DSS (West=79%, Central=85%, East=75%, p = 0.007) were significantly different, but there was no difference in RFS (West 47%, Central 48%, East 46%, p = 0.88). Multivariable linear regression analysis demonstrated that the differences in survival were independent of region OS (p = 0.78), DSS (p = 0.30) or RFS (p = 0.43).Conclusion: There is significant disparity in practice patterns between regions within Canada, but these do not appear to have an effect on survival. We believe that the variability in practice is a reflection of the lack of standardized treatments for UTUC and underlines the need for multi-institutional studies in this disease.
- 10 December 2012
- Published by Canadian Urological Association Journal in Canadian Urological Association Journal
- Vol. 6 (6) , 455-62
Regional differences in practice patterns and associated outcomes for upper tract urothelial carcinoma in Canada
Introduction: We delineated Canadian regional differences in practice patterns in the management of upper tract urothelial carcinoma (UTUC) after nephroureterectomy and relate these to patient outcomes.Methods: A database was created with 1029 patients undergoing radical nephroureterectomy for UTUC between 1994 and 2009 at 10 Canadian centres. Demographic, clinical and pathological variables were collected from chart review. Practice pattern variables were defined as: open versus laparoscopic nephroureterectomy, management strategy for the distal ureter, performance of lymphadenectomy and administration of chemotherapy and/or radiation therapy. The outcome measures were overall (OS), disease-specific (DSS) and recurrence-free survival (RFS). The centres were divided into three regions (West, Central, East). Cox proportional multivariable linear regression analysis was used to determine the association between regional differences in practice patterns and clinical outcomes.Results: There was a significant difference in practice patterns between regions within Canada for: time from diagnosis to surgery (p = 0.001), type of surgery (open vs. laparoscopic, p < 0.01) and method of management of the distal ureter (p = 0.001). As well, there were significant differences in survival between regions across Canada: 5-year OS (West 70%, Central 81% and East 62%, p < 0.0001) and DSS (West=79%, Central=85%, East=75%, p = 0.007) were significantly different, but there was no difference in RFS (West 47%, Central 48%, East 46%, p = 0.88). Multivariable linear regression analysis demonstrated that the differences in survival were independent of region OS (p = 0.78), DSS (p = 0.30) or RFS (p = 0.43).Conclusion: There is significant disparity in practice patterns between regions within Canada, but these do not appear to have an effect on survival. We believe that the variability in practice is a reflection of the lack of standardized treatments for UTUC and underlines the need for multi-institutional studies in this disease.
- 6 February 2012
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 72 (4 Suppleme) , A16
Abstract A16: A phase I/II clinical trial of a MUC1-glycopeptide dendritic cell vaccine in castrate resistant non-metastatic prostate cancer patients
Background: Current treatment options for prostate cancer (PCa) patients with rising PSA despite castrate testosterone levels are limited. A number of immunotherapeutic approaches for the treatment of PCa have been studied with varying efficacy. MUC1 has been an antigen of interest for immunotherapy, however, tolerance to the peptide epitopes has led to limited immune response. A glycosylated version of the antigen, Tn-100mer-MUC1, was shown to be effective in overcoming tolerance in pre-clinical studies. Dendritic cells (DC) take up and process Tn-100mer-MUC1 and present both glycopeptide and peptide epitopes. We report the results of a phase I/II clinical trial of an autologous DC vaccine loaded with Tn-100mer-MUC1 and KLH in patients with castrate resistant, non-metastatic PCa.
- 6 February 2012
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 72 (4 Suppleme) , A16
Abstract A16: A phase I/II clinical trial of a MUC1-glycopeptide dendritic cell vaccine in castrate resistant non-metastatic prostate cancer patients
Background: Current treatment options for prostate cancer (PCa) patients with rising PSA despite castrate testosterone levels are limited. A number of immunotherapeutic approaches for the treatment of PCa have been studied with varying efficacy. MUC1 has been an antigen of interest for immunotherapy, however, tolerance to the peptide epitopes has led to limited immune response. A glycosylated version of the antigen, Tn-100mer-MUC1, was shown to be effective in overcoming tolerance in pre-clinical studies. Dendritic cells (DC) take up and process Tn-100mer-MUC1 and present both glycopeptide and peptide epitopes. We report the results of a phase I/II clinical trial of an autologous DC vaccine loaded with Tn-100mer-MUC1 and KLH in patients with castrate resistant, non-metastatic PCa.